Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 9/20 | 0.43 |
| ▸ | METAP2 | P50579 | 3/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15685008 | 0.86 | F2 (0.51) | BCHEF2 | |
| Hydrochloric Acid SCHEMBL6741069 | 0.85 | F2 (0.50) | BCHEF2 | |
| SCHEMBL6881666 | 0.83 | BCHE (0.42) | CD274LMNAP4HTMBCHEMAOA | |
| SCHEMBL6882105 | 0.83 | GCK (0.41) | METAP1METAP2LMNATSHRHTT | |
| SCHEMBL6740580 | 0.82 | BCHE (0.51) | HTTBCHEMAOB | |
| SCHEMBL6882948 | 0.78 | TSHR (0.38) | METAP1METAP2LMNATSHRHTT | |
| Bromide SCHEMBL6876839 | 0.77 | TSHR (0.37) | METAP1METAP2LMNATSHRHTT | |
| SCHEMBL6881662 | 0.76 | P4HTM (0.38) | LMNAP4HTMMAOAMAOB | |
| SCHEMBL24372405 | 0.75 | CD274 (0.60) | CD274LMNAP4HTMBCHEMAOA | |
| SCHEMBL6876858 | 0.74 | GCK (0.38) | METAP1METAP2LMNAHTTBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040158066-A1 | Novel pyridylmethylaminopyrimidines | ALTANA PHARMA AG (DE) | 2004-08-12 | — | — | US | disclosed |
| EP-1395592-A1 | NOVEL PYRIDYLMETHYLAMINOPYRIMIDINES | ALTANA Pharma AG (DE) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094831-A1 | NOVEL PYRIDYLMETHYLAMINOPYRIMIDINES | ALTANA PHARMA AG (DE) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158066-A1 | Novel pyridylmethylaminopyrimidines | PGLS, PLPBP, PDXK | METAP1 680/4885METAP2 759/4885CD274 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.